FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308383462> ?p ?o ?g. }

• W4308383462 abstract "<h3>Background</h3> EO2401 was designed to activate memory T cells cross-reacting with tumor associated antigens. EO2401 includes synthetically produced HLA-A2 peptides with molecular mimicry to antigens (IL13Rα2, BIRC5 and FOXM1) upregulated in glioblastoma, and the CD4 helper peptide UCP2. <h3>Methods</h3> Patients with glioblastoma at first progression after radiotherapy/temozolomide received EO2401 (300 µg/peptide, q2w x4 then q4w) with nivolumab (3 mg/kg q2w; EN-regimen), or EN with bevacizumab (10 mg/kg q2w; ENB-regimen). In study part 2, low-dose bevacizumab (LDB) (5 mg/kg q2w up to 6 doses) could be used as symptom directed treatment of edema. The study, NCT04116658, was approved by all participating institution’s Ethics Boards. <h3>Results</h3> Part 1 included 40 patients (EN = 29, ENB = 11). Part 2 enrolled 36 patients treated with EN, and the possibility of symptom directed LDB. In study part 3, 15 further patients are to be treated with ENB (enrollment ongoing). EN and ENB were well tolerated with EO2401 associated tox limited to local administration site reactions (45% of patients; events 70% Grade 1, 26% Grade 2, and 4% Grade 3). The frequency and severity of nivolumab-/bevacizumab-tox was consistent with historical single-agent data. Immune monitoring demonstrated positive responses against the 3 microbiome-derived peptides for 28 of 29 patients investigated ex vivo or after in vitro stimulation (IVS). For some patients, positive response was already detected two weeks after the first vaccination and was maintained for more than 10 months. Cross-reactivity against the pool of 3 human target peptides was demonstrated in 27 of 28 patients using IFN-γ ELISpot assay. For part 1, median progression-free survival (mPFS), and median survival for EN (n=29, median follow-up 14.0 months) were 1.8 and 10.6 months. Patients on ENB (n=11, median follow-up 9.6 months) had mPFS of 5.5 months and 9 patients were alive (7-12.4 months). Objective Response Rate (ORR)/Disease Control Rate (DCR) (ORR + stable disease) for EN and ENB were 10%/34% and 55%/82%. Median treatment duration for EN in part 1 was 8.9 weeks (2 of 29 on treatment), while it was 12.0 weeks (21 of 36 on treatment) in part 2. Overall, in part 2, 13 patients (36%) received LDB. <h3>Conclusions</h3> EO2401 was well tolerated and generated fast and durable immune responses in most patients. Addition of standard bevacizumab to EN improved PFS and ORR/DCR. Symptom directed LDB supported longer treatment durations. Updated safety, immunogenicity, and efficacy data from all parts of the trial will be presented. <h3>Trial Registration</h3> NCT04116658 <h3>Ethics Approval</h3> This study has obtained an ethics approval (Dana Farber Cancer Institute IRB: iRIS number 438532) and all participants gave informed consent before taking part." @default.
• W4308383462 created "2022-11-11" @default.
• W4308383462 creator A5001189323 @default.
• W4308383462 creator A5003613132 @default.
• W4308383462 creator A5015090277 @default.
• W4308383462 creator A5016964659 @default.
• W4308383462 creator A5021656597 @default.
• W4308383462 creator A5027750043 @default.
• W4308383462 creator A5038523742 @default.
• W4308383462 creator A5040945122 @default.
• W4308383462 creator A5043463827 @default.
• W4308383462 creator A5059965175 @default.
• W4308383462 creator A5062510457 @default.
• W4308383462 creator A5066290988 @default.
• W4308383462 creator A5068953785 @default.
• W4308383462 creator A5071234082 @default.
• W4308383462 creator A5071617604 @default.
• W4308383462 creator A5073618375 @default.
• W4308383462 creator A5076037934 @default.
• W4308383462 creator A5080482957 @default.
• W4308383462 creator A5087244685 @default.
• W4308383462 creator A5091648075 @default.
• W4308383462 date "2022-11-01" @default.
• W4308383462 modified "2023-09-25" @default.
• W4308383462 title "642 EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1–2 EOGBM1–18/ROSALIE study" @default.
• W4308383462 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0642" @default.
• W4308383462 hasPublicationYear "2022" @default.
• W4308383462 type Work @default.
• W4308383462 citedByCount "0" @default.
• W4308383462 crossrefType "proceedings-article" @default.
• W4308383462 hasAuthorship W4308383462A5001189323 @default.
• W4308383462 hasAuthorship W4308383462A5003613132 @default.
• W4308383462 hasAuthorship W4308383462A5015090277 @default.
• W4308383462 hasAuthorship W4308383462A5016964659 @default.
• W4308383462 hasAuthorship W4308383462A5021656597 @default.
• W4308383462 hasAuthorship W4308383462A5027750043 @default.
• W4308383462 hasAuthorship W4308383462A5038523742 @default.
• W4308383462 hasAuthorship W4308383462A5040945122 @default.
• W4308383462 hasAuthorship W4308383462A5043463827 @default.
• W4308383462 hasAuthorship W4308383462A5059965175 @default.
• W4308383462 hasAuthorship W4308383462A5062510457 @default.
• W4308383462 hasAuthorship W4308383462A5066290988 @default.
• W4308383462 hasAuthorship W4308383462A5068953785 @default.
• W4308383462 hasAuthorship W4308383462A5071234082 @default.
• W4308383462 hasAuthorship W4308383462A5071617604 @default.
• W4308383462 hasAuthorship W4308383462A5073618375 @default.
• W4308383462 hasAuthorship W4308383462A5076037934 @default.
• W4308383462 hasAuthorship W4308383462A5080482957 @default.
• W4308383462 hasAuthorship W4308383462A5087244685 @default.
• W4308383462 hasAuthorship W4308383462A5091648075 @default.
• W4308383462 hasBestOaLocation W43083834621 @default.
• W4308383462 hasConcept C121608353 @default.
• W4308383462 hasConcept C126322002 @default.
• W4308383462 hasConcept C143998085 @default.
• W4308383462 hasConcept C147483822 @default.
• W4308383462 hasConcept C203014093 @default.
• W4308383462 hasConcept C2776694085 @default.
• W4308383462 hasConcept C2777389519 @default.
• W4308383462 hasConcept C2777701055 @default.
• W4308383462 hasConcept C2777802072 @default.
• W4308383462 hasConcept C2780030458 @default.
• W4308383462 hasConcept C2781413609 @default.
• W4308383462 hasConcept C509974204 @default.
• W4308383462 hasConcept C71924100 @default.
• W4308383462 hasConcept C90924648 @default.
• W4308383462 hasConceptScore W4308383462C121608353 @default.
• W4308383462 hasConceptScore W4308383462C126322002 @default.
• W4308383462 hasConceptScore W4308383462C143998085 @default.
• W4308383462 hasConceptScore W4308383462C147483822 @default.
• W4308383462 hasConceptScore W4308383462C203014093 @default.
• W4308383462 hasConceptScore W4308383462C2776694085 @default.
• W4308383462 hasConceptScore W4308383462C2777389519 @default.
• W4308383462 hasConceptScore W4308383462C2777701055 @default.
• W4308383462 hasConceptScore W4308383462C2777802072 @default.
• W4308383462 hasConceptScore W4308383462C2780030458 @default.
• W4308383462 hasConceptScore W4308383462C2781413609 @default.
• W4308383462 hasConceptScore W4308383462C509974204 @default.
• W4308383462 hasConceptScore W4308383462C71924100 @default.
• W4308383462 hasConceptScore W4308383462C90924648 @default.
• W4308383462 hasLocation W43083834621 @default.
• W4308383462 hasOpenAccess W4308383462 @default.
• W4308383462 hasPrimaryLocation W43083834621 @default.
• W4308383462 hasRelatedWork W2107163829 @default.
• W4308383462 hasRelatedWork W2234353674 @default.
• W4308383462 hasRelatedWork W2462822954 @default.
• W4308383462 hasRelatedWork W2612637619 @default.
• W4308383462 hasRelatedWork W3004632817 @default.
• W4308383462 hasRelatedWork W3115829157 @default.
• W4308383462 hasRelatedWork W3136872646 @default.
• W4308383462 hasRelatedWork W3160665980 @default.
• W4308383462 hasRelatedWork W3216431241 @default.
• W4308383462 hasRelatedWork W3216515756 @default.
• W4308383462 isParatext "false" @default.
• W4308383462 isRetracted "false" @default.
• W4308383462 workType "article" @default.